KROS News and Press, Keros Therapeutics Inc. From 01/04/24

2024-01-04 01:04:56 ET More on Keros Therapeutics Keros Therapeutics: Interesting Early Data From A Promising Molecule (Downgrade) Keros falls after mid-stage data for blood cancer therapy Seeking Alpha’s Quant Rating on Keros Therapeutics For further ...

LEXINGTON, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “we”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that ...

2024-01-03 16:34:46 ET Gainers: iHeartMedia ( IHRT ) +10% . Arcutis Biotherapeutics ( ARQT ) +8% . Cipher Mining  ( CIFR ) +7% . Pacira BioSciences ( PCRX ) +6% . Argo Blockchain  ( ARBK ) +6% . Losers: Cal-Main...

2024-01-03 16:12:08 ET More on Keros Therapeutics Keros Therapeutics: Interesting Early Data From A Promising Molecule (Downgrade) Keros falls after mid-stage data for blood cancer therapy Seeking Alpha’s Quant Rating on Keros Therapeutics For further ...

2024-01-03 14:25:48 ET Summary Keros Therapeutics, Inc. has three clinical stage programs targeting blood cells, blood vessels, and heart tissues by disrupting TGF-β signaling. Phase 2 data for their lead asset, KER-050, showed sustained transfusion independence in patients...

Keros commenced a randomized, double-blind, placebo-controlled, two-part Phase 1 clinical trial to evaluate single and multiple ascending doses of KER-065 in healthy volunteers Keros expects to report initial data from this Phase 1 clinical trial in the first quarter of 2025 Precl...

2023-12-30 21:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-11 13:09:09 ET More on Keros Therapeutics Seeking Alpha’s Quant Rating on Keros Therapeutics Historical earnings data for Keros Therapeutics Financial information for Keros Therapeutics For further details see: Keros falls after mid-stage d...

KER-050 (elritercept) achieved durable transfusion independence in lower-risk MDS, including in patients with high transfusion burden Durable clinical responses were associated with improvements in patient-reported measures of fatigue Biomarker data demonstrate that KER-050 trea...

2023-11-06 13:19:56 ET More on Keros Therapeutics Seeking Alpha’s Quant Rating on Keros Therapeutics Historical earnings data for Keros Therapeutics Financial information for Keros Therapeutics For further details see: Keros Therapeutics GAAP EPS o...